Ultragenyx reports Q3 2026 loss, FDA approvals and outlines 2027 profitability plan
Ultragenyx Pharmaceutical posted third‑quarter 2026 revenue of $173 million and a net loss of $118 million, or $1.16 per share. The company received FDA approvals for its gene therapies GENGLYCOS and FAYUVI and sold the associated priority‑review vouchers for a combined $413 million. It announced a 20% headcount cut, ending two clinical programs (GTX‑102 and UX701), and said it will limit 2027 R&D spending to under $350 million and SG&A to under $375 million, reaffirming full‑year 2026 revenue guidance of $730 million‑$760 million and targeting GAAP profitability in 2027.
Why it matters
The company expects the $350 million net proceeds from the voucher sales and the 50%‑plus expense reductions to drive GAAP profitability in 2027, according to its own guidance. Analysts note that the profitability plan and cash infusion could improve the firm’s financial outlook.
Key facts
- 1Total revenue in the third quarter 2026 was $173 million. sec.gov
- 2Net loss for the quarter was $118 million, or $1.16 per share basic and diluted. sec.gov
- 3The FDA approved GENGLYCOS™ and FAYUVI™ BLAs in the third quarter. sec.gov
- 4Two priority‑review vouchers were sold for a combined price of $413 million. sec.gov
- 5Headcount is being reduced by approximately 20%, to about 1,000 employees. sec.gov
- 6R&D expenses for 2027 are targeted to be less than $350 million. sec.gov
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.